Form 4: Glycomimetics Executive Sells Shares
Insider Transaction (Form 4)
Jan Pinkas, Chief Scientific Officer of Glycomimetics Inc, sold 658 shares of common stock on September 16, 2026 for $17.90 per share.
Summary
- Open-market sale: disposed of 658 Ordinary Shares at $17.90 ($11,778) on September 16, 2026; holds 21,581 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $11,778 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jan Pinkas — Officer (Chief Scientific Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Open-market sale | Ordinary Shares | 658 | $18 | $11.8K | 21,581 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Open-market sale (658 shares) |
Keywords
insider transaction, Form 4, CBIO, CRESCENT BIOPHARMA, INC., bearish, Jan Pinkas
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.